




RealRate

PHARMACEUTICAL 2022

Immune Therapeutics Inc.
Rank 282 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

Immune Therapeutics Inc. Rank 282 of 475

The relative strengths and weaknesses of Immune Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Immune Therapeutics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 143% points.

The company's Economic Capital Ratio, given in the ranking table, is -165%, being 111% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	3,139
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,087
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	0
Research and Development	153
Revenues	0
Selling, General and Administrative Expense	586

Output Variable	Value in 1000 USD
Assets	3,139
Liabilities	11,087
Expenses	738
Stockholders Equity	-7,948
Net Income	-738
Comprehensive Net Income	-738
Economic Capital Ratio	-165%

